ArticleBMJ open2020
Lung cancer survival and mortality in Taiwan following the initial launch of targeted therapies: an interrupted time series study.
Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Treatment Patterns in Early Stage NSCLC in Asia: Findings From the ELEVATE Study.JTO clinical and research reports · 2026Article
- Virtual screening of novel alkaloids as potent inhibitors for G2032R-mutant ROS1 kinase in non-small-cell lung cancer.Scientific reports · 2026Article
- Rebiopsy Enhances Survival with Afatinib vs. Osimertinib in EGFR Exon 19 Deletion Non-Small Cell Lung Cancer: A Multicenter Study in Taiwan.Current oncology (Toronto, Ont.) · 2025Article
- Predicting Lung Cancer Survival to the Future: Population-Based Cancer Survival Modeling Study.JMIR public health and surveillance · 2024Article
- C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer.World journal of surgical oncology · 2024Article
- Oral administration of oligo fucoidan improves the survival rate, quality of life, and immunity in patients with lung cancer.Food & nutrition research · 2024Article
- Influence of Rifamycin on Survival in Patients with Concomitant Lung Cancer and Pulmonary Tuberculosis.Biomedicines · 2023Article
- Simulation education utilizing phantom and angle reference guide in pulmonary nodule CT localization.Heliyon · 2023Article
- [Long-term Survival in Hospitalized Patients with Lung Cancer among Peasants in the Coal-producing Area in Eastern Yunnan, China].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Changes in survival of patients with non-small cell lung cancer in Japan: An interrupted time series study.Cancer science · 2023Article
- Survival of Lung Cancer Patients by Histopathology in Taiwan from 2010 to 2016: A Nationwide Study.Journal of clinical medicine · 2022Article
- CirculatingInternational journal of molecular sciences · 2022Article
- How Is the Lung Cancer Incidence Rate Associated with Environmental Risks? Machine-Learning-Based Modeling and Benchmarking.International journal of environmental research and public health · 2022Article
- Thoracic surgery in Taiwan.Journal of thoracic disease · 2022Review
- The Downregulation ofJournal of personalized medicine · 2021Article
- Efficacy and Prognosis of First-Line EGFR-Tyrosine Kinase Inhibitor Treatment in Older Adults Including Poor Performance Status Patients withCancer management and research · 2021Article
- Downregulation of FHOD1 Inhibits Metastatic Potential in A549 Cells.Cancer management and research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTwo oral targeted therapies, gefitinib and erlotinib, were first approved and then launched into the market for treatment of late-stage non-small cell lung cancer (NSCLC) in Taiwan in 2003 and 2006, respectively. The aim of this study were to determine the trends in lung cancer burden and examine changes in lung cancer-related survival rates and mortality following the launch of these new drugs.
settingYearly lung cancer-related data (1994-2013), including incidence, number of newly diagnosed patients, survival rate and mortality, were retrieved from the Taiwan Cancer Registry Database. DESIGN AND OUTCOME MEASURES: Using a time series design with autoregressive integrated moving average model, we investigated and projected trends in the incidence and early diagnosis of lung cancer in Taiwan. We also estimated the changes in survival rates and mortality following the launch of targeted therapies using interrupted time series and segmented regression models.
resultsThe age-standardised incidence of lung cancer increased from 22.53 per 100 000 people in 1994 to 34.09 in 2013, and it was projected to reach 38.98 by 2020. The rate of early-stage NSCLC at diagnosis increased from 12.63% in 2004 to 23.99% in 2013, and it was projected to reach 32.95% by 2020. The 2-year lung cancer survival increased by 19.81% (95% CI 14.90% to 24.71%) 3 years following the launch of gefitinib. Lung cancer mortality declined by 5.97% (95% CI -8.20% to -3.73%) 3 years following the launch of gefitinib.
conclusionsLung cancer survival rate increased and mortality decreased significantly following the launch of gefitinib and erlotinib in Taiwan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.